SciSparc Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SPRC Nasdaq 2830 scisparc.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for SciSparc Ltd.

SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum - Jun 4th, 2026 5:32 am
NeuroThera Labs Inc. Announces Closing of Acquisition of Majority Stake in CliniQuantum Ltd. - Jun 3rd, 2026 4:04 pm
SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum - May 28th, 2026 6:40 am
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - Mar 16th, 2026 6:20 am
NeuroThera Labs - Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - Mar 16th, 2026 5:30 am
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy - Mar 13th, 2026 5:45 am
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Mar 12th, 2026 5:55 am
NeuroThera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Mar 11th, 2026 5:30 am
SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails - Mar 10th, 2026 7:28 am
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Mar 10th, 2026 6:59 am
Neurothera Labs Inc. Announces Definitive Agreement to Acquire Majority Stake in Cliniquantum Ltd. - Mar 10th, 2026 5:30 am
SciSparc announces 1-for-9 reverse share split - Mar 3rd, 2026 6:23 am
SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA - Feb 2nd, 2026 6:24 am
Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance Such as MRSA - Feb 2nd, 2026 6:00 am
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization - Jan 26th, 2026 6:13 am
SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity - Jan 13th, 2026 4:55 am
SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance - Jan 12th, 2026 2:02 pm
SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects - Dec 30th, 2025 6:17 am
Neurothera Labs Granted Patent by Israeli Patent Office for Its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects - Dec 30th, 2025 6:00 am
IM Cannabis Appoints Asi Levi as Chief Financial Officer - Dec 12th, 2025 2:01 pm